Deep brain stimulation surgery complicated by Parkinson hyperpyrexia syndrome
Sir, Parkinson-hyperpyrexia syndrome (PHS) is a medical emergency described in patients with Parkinson's Disease (PD) who abruptly stop levodopa treatment, and is characterized by autonomic instability, tremor, rigidity and rhabdomyolysis. PHS after deep brain stimulation (DBS) is extremely rare and may have distinctive characteristics. [1] This report presents the fourth patient with PHS after DBS.
A 59-year-old male, a known case of PD since 22 years was admitted for globus pallidus interna (GPi) DBS surgery. Twelve hours before surgery all PD medication was stopped. After the procedure he was febrile, unable to open eyes or respond to commands and developed severe tremor and rigidity of entire body. Computed tomography scan showed no abnormalities. Blood biochemistry showed serum creatine kinase (CK) elevation. With a diagnosis of PHS he was started on dopamine agonist and dantrolene. Symptoms gradually resolved. Six months after discharge the electrodes were turned on with significant motor improvement.
Till date only three patients with PHS after DBS have been reported. [2] [3] [4] The clinical features in our patient were similar to the other three patients: hyperthermia, tachycardia and hypertension, and rigidity. Our patient in addition had severe tremor and significant altered mental status, which were of much lesser degree in the other three patients. Linazasoro et al. [4] reported a case with no rigidity or tremors and speculated that the micro trauma of the subthalamic nucleus (STN) might have had a "therapeutic" effect, changing the clinical expression of PHS and thus delaying the diagnosis in their patient. There are no reliable guidelines to discontinue PD medication either gradually or acutely before DBS surgery and this needs further study. However, in all the four patients including our patient, who developed PHS after DBS, PD medication was discontinued acutely. Although infrequent, PHS should be considered and excluded when the postoperative course deviates from its normal.
Anti-Ma2-positive paraneoplastic brainstem encephalitis associated with prostatic adenocarcinoma
Sir, Paraneoplastic neurological syndromes (PNS) are considered to be autoimmune-mediated disorders of the nervous system. In 1999, Voltz [1] detected an antibody against the Ma2 protein in tumors as well as in normal brain tissue of patients with paraneoplastic limbic/brainstem encephalitis and germ cell cancer. PNS are seldom associated with prostate cancer, and paraneoplastic brainstem encephalitis due to prostate cancer is very uncommon. Brainstem, diencephalic and limbic encephalopathy are associated with Ma2 antibodies. Prostate cancer alone has not been associated with anti-Ma2 antibodies.
A 62-year-old man, a diagnosed case of local adenocarcinoma of prostate, presented with diplopia and dysarthria of three weeks' duration. Neurologic examination revealed left sixth nerve palsy, right fourth nerve palsy, bilateral ptosis, vertical gaze palsy, facial diplegia, hoarseness of voice, dysarthria and dysphagia. Cerebrospinal fluid (CSF) examination was normal and no oligoclonal bands were found. Laboratory evaluation for sarcoidosis, borrelia, Wegener's granulomatosis, HIV types 1 and 2, varicella-zoster and HHV-6 was negative. Electrophysiological investigations were normal. An initial contrast brain magnetic resonance imaging (MRI) and a repeat contrast MRI after one month were normal.
A whole-body computed tomography (CT) scan revealed no abnormality. Recombinant immunoblotting was negative against Hu/Yo/Ri/CV2/amphiphysin/Ma1/ Tr antibodies but was positive against Ma2 in serum and CSF. The positive antibody test result was confirmed in an independent laboratory. His prostate-specific antigen (PSA) was 2.0 (normal <4 µg/L). Carcinoembryonic antigen (CEA), beta human chorionic gonadotropin (ß-HCG) and alpha-fetoprotein (AFP) were normal. Testicular ultrasound was normal. MRI of the testicles/ pelvis and abdomen/chest displayed normality. Positron-emission tomography (PET) CT, whole-body 18-fluorodeoxyglucose-PET/CT revealed no evidence of testicular tumor or disseminated prostate cancer or other tumors. A bone scan and a spinal MRI were normal. Corticosteroids and plasmapheresis improved his symptoms. He remains symptom-free.
The case study highlights a patient with brainstem encephalitis and prostate cancer where evaluations revealed Ma2 antibodies. Paraneoplastic brainstem encephalitis associated with prostate cancer is very rare. In 1993, Baloh [2] reported two patients with unusual brainstem syndromes associated with prostate cancer, and CSF in both the patients showed mild pleocytosis and elevated immunoglobulin G. No paraneoplastic antibodies were detected. Berger [3] described a patient with a paraneoplastic brainstem syndrome associated with prostate cancer. The authors for the first time demonstrated an antibody in both serum and CSF directed against intraneuronal antigens, but the target antigen was not identified. Clinically, Ma2 antibodies have been correlated with symptoms associated with limbic, diencephalic, or brainstem encephalopathy. [4] Dalmau [5] studied the clinical findings of cancer patients with anti-Ma2-associated encephalitis. The majority of the patients developed symptoms of limbic, diencephalic or brainstem dysfunction. In the study by Gultekin [6] patients with anti-Ma2 antibodies were young men with testicular germ-cell tumors (100%) and with frequent hypothalamic involvement and a poor neurological outcome. Thus testicular carcinoma should be ruled out in younger men displaying a Ma2 paraneoplastic syndrome. In men over 50 years old and in women other tumors such as lung cancer and breast cancer should be excluded. [7] The presence of prostate cancer and of Ma2 antibodies proves paraneoplastic etiology as the cause of the brainstem encephalitis. [8] In conclusion, this case study strongly suggests an association between the patient's Ma2 antibodies and the prostate cancer. However, it cannot be proved, based on this case, whether the anti-Ma2 reactivity in this patient is specific for prostate cancer or not. The detection of anti-Ma2 reactivity in an older male with unexplained subacute predominant upper brainstem dysfunction
